Abstract 149P
Background
Microsatellite instability-high (MSI-H) is one of the biomarkers for response to anti-PD-1 antibody for solid tumors including gastric cancer (GC) or gastroesophageal junction cancer (GEJC). Characteristics of patients with MSI-H G/GEJC are not well-known. We conducted a prospective observational study as screening for WJOG13320G, a single arm phase 2 trial of Nivolumab plus low dose Ipilimumab (jRCT2080225304), and to clarify the prevalence and clinicopathological features of chemotherapy-naïve MSI-H advanced G/GEJC.
Methods
Key inclusion criteria were following; histologically confirmed unresectable locally advanced or metastatic adenocarcinoma of stomach or GEJ, ECOG PS of 0 or 1, age of at least 20 years, no prior systemic anticancer therapy for advanced or metastatic disease and adequate organ function. Formalin-fixed paraffin-embedded tissue from biopsy or surgical specimens was used for the MSI-IVD Kit (FALCO). The primary endpoint was the proportion of patients with MSI-H in chemotherapy-naïve G/GEJC and a key secondary endpoint was clinicopathological features of MSI-H advanced G/GEJC.
Results
Between Oct. 2020 and Oct. 2022, 935 patients from 75 centers in Japan were registered. Because of 2 withdrawal and 3 ineligible, 930 patients were analyzed. The male: female ratio was 69:31 and median age was 70 (range; 24-88) years. All specimens were successfully tested, with a median turn-around-time of 7 (range; 3-37) days. The proportion of MSI-H G/GEJC was 5.6 (95% CI; 4.2-7.3) %. MSI-H was more frequent in female (9.6%) than in male (3.8%; p<0.01), in lower stomach (10.5%) than in upper/middle stomach or GEJ (2.1/3.7/4.0%; p<0.01), in patients without liver metastases (6.9%) than in those with liver metastases (2.2%, p<0.01) and in HER2-negative (6.5%) than in HER2-positive (1.8%, p=0.02). The median age was higher in MSI-H patients (74 years) than in non-MSI-H patients (70 years, p<0.01).
Conclusions
The proportion of MSI-H in unresectable chemotherapy-naïve advanced G/GEJC was 5.6%. MSI-H G/GEJC was characterized by female, older age, lower stomach, no liver metastases, and HER2-negative.
Clinical trial identification
UMIN000040366.
Editorial acknowledgement
Legal entity responsible for the study
West Japan Oncology Group.
Funding
Bristol Myers Squibb Company, FALCO biosystems Ltd.
Disclosure
Y. Narita: Financial Interests, Personal, Invited Speaker: Yakult, Taiho, Eli Lilly, Daiichi Sankyo, Ono pharma, BMS; Financial Interests, Personal, Advisory Board: Daiichi Sankyo; Financial Interests, Institutional, Local PI: Ono pharma, BMS, AstraZeneca, Diaiichi Sankyo. S. Hironaka: Financial Interests, Personal, Other, lecture: Ono Pharm, BMS, Eli Lilly, Taiho, Daiichi Sankyo, MSD, Chugai, Merck Biopharma, Takeda, Yakult Honsha. H. Kawakami: Financial Interests, Personal, Invited Speaker: Bristol Myers Squibb Co. Ltd., Ono Pharmaceutical Co. Ltd, Daiichi Sankyo Co. Ltd., Bayer Yakuhin Ltd, Eli Lilly Japan K.K., MSD K.K., Chugai Pharmaceutical Co. Ltd., Merck Biopharma Co., Ltd., Takeda Pharmaceutical Co. Ltd., Yakult Pharmaceutical Industry, Teijin Pharma Ltd., Taiho Pharmaceutical Co. Ltd.; Financial Interests, Personal, Advisory Board: Daiichi Sankyo Co. Ltd.; Financial Interests, Personal, Other, Lecture: GSK K.K, Otsuka Pharmaceutical Co., Ltd.; Financial Interests, Institutional, Research Grant, Investigator-Initiated Trial: Bristol Myers Squibb Co. Ltd.; Financial Interests, Institutional, Research Grant: Taiho Pharmaceutical Co. Ltd, Eisai Co., Ltd., Kobayashi Pharmaceutical Co. Ltd., PAREXEL International Corp., PRA HEALTHSCIENCES, EPS Corporation., Kissei Pharmaceutical Co., Ltd., EPS International Co., Ltd,., MSD K.K., Ono Pharmaceutical Co., Ltd., PPD-SNBL K.K, SymBio Pharmaceuticals Limited., IQVIA Services JAPAN K.K., Syneos Health Clinical K.K., Nippon Kayaku Co., Ltd., EP-CRSU Co., Ltd., Eisai Co., Ltd., Mebix, Inc., Bristol Myers Squibb K.K., Janssen Pharmaceutical K.K., AstraZeneca K.K., Mochida Pharmaceutical Co., Ltd., Covance Japan Inc., Japan Clinical Research Operations, Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., GSK K.K., Sanofi K.K., Nippon Boehringer Ingelheim Co., Ltd., Sysmex Corporation, Novartis Pharma K.K., Otsuka Pharmaceutical Co., Ltd., SRL, Inc., Daiichi Sankyo Co., Ltd., Amgen Inc., Medical Reserch Support, Eli Lilly Japan K.K. M. Furuta: Financial Interests, Personal, Invited Speaker: Eli Lilly, Bristol Myers Squibb, Merck & Co., Inc., Ono Pharmaceutical CO., LTD., Takeda Pharmaceutical Company Limited. T. Kawakami: Financial Interests, Personal, Advisory Board: Daiichi Sankyo; Financial Interests, Personal, Other, honoraria: Bristol Myers Squibb, Ono Pharmaceutical, Yakult Honsha, Daiichi Sankyo. A. Makiyama: Financial Interests, Personal, Invited Speaker: Eli Lilly, Taiho, Ono, Daiichi Sankyo, Bristol Myers Squibb. H. Hirano: Financial Interests, Personal, Invited Speaker: Taiho Pharmaceutical, Ono Pharmaceutical, Teijin Phama, Novartis; Financial Interests, Personal, Writing Engagement: Nichi-Iko; Financial Interests, Institutional, Research Grant: Chugai Pharmaceutical, Daiichi Sankyo, Taiho Pharmaceutical, Ono Pharmaceutical, Janssen Pharmaceutical, Merck Biopharma, Bristol Myers Squibb, Pfizer, Eisai, Amgen, Astellas, Seagen, MSD, Insyte, BeiGene, Novartis. M. Komoda: Financial Interests, Personal, Invited Speaker: Lilly Japan, Ono Pharmaceutical, Bristol Myers Squibb Japan, Eisai, Daiichi Sankyo/UCB Japan, Chugai Pharma, Taiho Pharmaceutical. T. Matsumoto: Financial Interests, Personal, Invited Speaker: Ono Pharmaceutical Co, Ltd, Bayer Co, Ltd, Bristol Myers Squibb Co, Ltd, Daiichi Sankyo Co, Ltd, Eli Lilly Japan Co, Ltd, Merck Bio Pharma Co, Ltd, MSD Co, Ltd, Taiho Pharmaceutical Co, Ltd, Takeda Co, Ltd. K. Yoshimura: Financial Interests, Personal, Invited Speaker: AstraZeneca, Chugai Pharma, MSD; Financial Interests, Personal, Advisory Board: Sysmex; Financial Interests, Personal, Writing Engagement: AstraZeneca. K. Muro: Financial Interests, Personal, Advisory Board: Amgen, AstraZeneca, Ono, Chugai; Financial Interests, Personal, Invited Speaker: Eli Lilly, Ono, Daiichi Sankyo, Taiho, Bristol Myers Squibb, Takeda; Financial Interests, Institutional, Research Grant, Including local PI as role: Astellas, Amgen, Sanofi, Daiichi Sankyo, Taiho, MSD, Pfizer, Merck Biopharma, Eisai, Ono, Novartis; Financial Interests, Personal, Steering Committee Member: Chugai, AstraZeneca, Amgen; Non-Financial Interests, Personal, Principal Investigator: Takeda. All other authors have declared no conflicts of interest.
Resources from the same session
111P - Comparison of the efficacy and safety of fruquintinib and fruquintinib combined with immune checkpoint inhibitors in the treatment of metastatic microsatellite stable colorectal cancer: A real-world study
Presenter: Zhiqiang Wang
Session: Poster Display
Resources:
Abstract
112P - Optimal classification and treatment strategy based on technical and oncological futures in recurrence of colorectal liver metastases
Presenter: Kosuke Kobayashi
Session: Poster Display
Resources:
Abstract
113P - Phase I/II study of capecitabine(C)/oxaliplatin(O)/irinotecan(I) combined with bevacizumab(B) in the first-line treatment of metastatic colorectal cancer (mCRC)
Presenter: Kai Ou
Session: Poster Display
Resources:
Abstract
114P - The prognostic role of LAG-3 expression in metastatic colorectal cancer
Presenter: Yi-Hsuan Huang
Session: Poster Display
Resources:
Abstract
115P - Sidedness and survival of chemo-refractory metastatic colorectal cancer treated with lonsurf or regorafenib: A nationwide population-based study in Taiwan
Presenter: Meng-Che Hsieh
Session: Poster Display
Resources:
Abstract
116P - Burden and trends of colorectal cancer in high income Asia Pacific countries from 1990-2019 and its projections of deaths to 2040: A comparative analysis
Presenter: Monika Chhayani
Session: Poster Display
Resources:
Abstract
117P - Australasian real-world treatment selection and clinical outcomes for patients with left side (LS), RAS wildtype (RASwt) metastatic colorectal cancer (mCRC)
Presenter: Vanessa Wong
Session: Poster Display
Resources:
Abstract
119P - Neoadjuvant chemoradiotherapy in the mode of hypofractionation in locally advanced rectal cancer: Is it time to change standards of care?
Presenter: Abror Abdujapparov
Session: Poster Display
Resources:
Abstract
120P - Improved clinical outcomes with cetuximab maintenance therapy in left-sided RAS/BRAF wild-type metastatic colorectal cancer: A real-world study of Hunan cancer hospital
Presenter: Xiaolin Yang
Session: Poster Display
Resources:
Abstract
121P - Single-cell sequencing reveals the role of Treg cells with high expression of BIRC3 in regulating the progression of colorectal cancer
Presenter: Yuqiu Xu
Session: Poster Display
Resources:
Abstract